Evidence map›Paper›PMID 24447629›Full record

Trial reportLife sciences2014

Effects of two lipid lowering therapies on immune responses in hyperlipidemic subjects.

Flavio Tocci Moreira, Silvia Cristina Ramos, Andrea Moreira Monteiro, Tatiana Helfenstein, Magnus Gidlund, Nagila Raquel Teixeira Damasceno, Antonio Martins Figueiredo Neto, Maria Cristina Izar, Francisco Antonio Helfenstein Fonseca

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Life sciences, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02428374 (Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study), which is not on this map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02428374 phase4unknown statusstarted 2015, after this paper: background citation

Role of Innate and Adaptive Immunity After Acute Myocardial Infarction BATTLE-AMI Study (B And T Types of Lymphocytes Evaluation in Acute Myocardial Infarction)

Ran2015Enrolled300Registered outcomes30Posted comparisons0ConditionsMyocardial FibrosisArmsRosuvastatin plus clopidogrel, Rosuvastatin plus ticagrelor, Simvastatin plus clopidogrel, Simvastatin plus ticagrelor
PMID 19329822PMID 20702973PMID 19942084PMID 15007110PMID 20031900PMID 22569318PMID 19764857PMID 21742096PMID 15975672PMID 19329177PMID 18997196PMID 18823627other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Flavio Tocci MoreiraDepartment of Medicine, Federal University of São Paulo, Sao Paulo, SP, Brazil.
Silvia Cristina RamosDepartment of Medicine, Federal University of São Paulo, Sao Paulo, SP, Brazil.
Andrea Moreira MonteiroComplex Fluids Laboratory, Institute of Physics, University of Sao Paulo, Sao Paulo, SP, Brazil.
Tatiana HelfensteinDepartment of Medicine, Federal University of São Paulo, Sao Paulo, SP, Brazil.
Magnus GidlundDepartment of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil.
Nagila Raquel Teixeira DamascenoDepartment of Nutrition, School of Public Health, University of Sao Paulo, SP, Brazil.
Antonio Martins Figueiredo NetoComplex Fluids Laboratory, Institute of Physics, University of Sao Paulo, Sao Paulo, SP, Brazil.
Maria Cristina IzarDepartment of Medicine, Federal University of São Paulo, Sao Paulo, SP, Brazil.
Francisco Antonio Helfenstein FonsecaDepartment of Medicine, Federal University of São Paulo, Sao Paulo, SP, Brazil. Electronic address: fahfonseca@terra.com.br.
Universidade Federal de São Paulo · BRUniversidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo compare the effects of two of the most effective lipid-lowering therapies with similar LDL-cholesterol reduction capacity on the innate and adaptive immune responses through the evaluation of autoantibodies anti-oxidized LDL (anti-oxLDL Abs) and electronegative LDL [LDL(-)] levels. MAIN

methodsWe performed a prospective, randomized, open label study, with parallel arms and blinded endpoints. One hundred and twelve subjects completed the study protocol and received rosuvastatin 40 mg or ezetimibe/simvastatin 10/40 mg for 12 weeks. Lipids, apolipoproteins, LDL(-), and anti-oxLDL Abs (IgG) were assayed at baseline and end of study. KEY

findingsMain clinical and laboratory characteristics were comparable at baseline. Lipid modifications were similar in both treatment arms, however, a significant raise in anti-oxLDL Abs levels was observed in subjects treated with rosuvastatin (p=0.026 vs. baseline), but not in those receiving simvastatin/ezetimibe. (p=0.233 vs. baseline), thus suggesting modulation of adaptive immunity by a potent statin. Titers of LDL(-) were not modified by the treatments. SIGNIFICANCE: Considering atherosclerosis as an immune disease, this study adds new information, showing that under similar LDL-cholesterol reduction, the choice of lipid-lowering therapy can differently modulate adaptive immune responses.

Indexed as

AntibodiesAzetidinesCholesterol, LDLEzetimibeFluorobenzenesHLA-D AntigensHumansHyperlipidemiasHypolipidemic AgentsImmune SystemPyrimidinesRosuvastatin CalciumSulfonamidesAntibodiesAzetidinesCholesterol, LDLEzetimibeFluorobenzenesHLA-D AntigensHypolipidemic AgentsPyrimidinesRosuvastatin CalciumSulfonamidesDyslipidemiaElectronegative low-density lipoproteinEzetimibeOxidized LDLStatins

Identifiers

PMID24447629
OpenAlexW1973567151

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.